These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 21840483)

  • 1. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression.
    Chen M; Pratt CP; Zeeman ME; Schultz N; Taylor BS; O'Neill A; Castillo-Martin M; Nowak DG; Naguib A; Grace DM; Murn J; Navin N; Atwal GS; Sander C; Gerald WL; Cordon-Cardo C; Newton AC; Carver BS; Trotman LC
    Cancer Cell; 2011 Aug; 20(2):173-86. PubMed ID: 21840483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma.
    Molina JR; Agarwal NK; Morales FC; Hayashi Y; Aldape KD; Cote G; Georgescu MM
    Oncogene; 2012 Mar; 31(10):1264-74. PubMed ID: 21804599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
    Nowak DG; Cho H; Herzka T; Watrud K; DeMarco DV; Wang VM; Senturk S; Fellmann C; Ding D; Beinortas T; Kleinman D; Chen M; Sordella R; Wilkinson JE; Castillo-Martin M; Cordon-Cardo C; Robinson BD; Trotman LC
    Cancer Discov; 2015 Jun; 5(6):636-51. PubMed ID: 25829425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PHLPP2 phosphatase is a druggable driver of prostate cancer progression.
    Nowak DG; Katsenelson KC; Watrud KE; Chen M; Mathew G; D'Andrea VD; Lee MF; Swamynathan MM; Casanova-Salas I; Jibilian MC; Buckholtz CL; Ambrico AJ; Pan CH; Wilkinson JE; Newton AC; Trotman LC
    J Cell Biol; 2019 Jun; 218(6):1943-1957. PubMed ID: 31092557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit.
    Bertacchini J; Mediani L; Beretti F; Guida M; Ghalali A; Brugnoli F; Bertagnolo V; Petricoin E; Poti F; Arioli J; Anselmi L; Bari A; McCubrey J; Martelli AM; Cocco L; Capitani S; Marmiroli S
    J Cell Physiol; 2019 Jul; 234(7):11188-11199. PubMed ID: 30565691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN and PHLPP crosstalk in cancer cells and in TGFβ-activated stem cells.
    Ghalali A; Ye ZW; Högberg J; Stenius U
    Biomed Pharmacother; 2020 Jul; 127():110112. PubMed ID: 32294598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and PH domain and leucine-rich repeat phosphatase cross-talk (PHLPP) in cancer cells and in transforming growth factor β-activated stem cells.
    Ghalali A; Ye ZW; Högberg J; Stenius U
    J Biol Chem; 2014 Apr; 289(17):11601-11616. PubMed ID: 24599953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
    Tan M; Xu J; Siddiqui J; Feng F; Sun Y
    Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.
    Yu Y; Dai M; Lu A; Yu E; Merlino G
    Oncogene; 2018 Apr; 37(17):2225-2236. PubMed ID: 29391600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between polycomb-group protein BMI-1 and phosphatases regulating AKT phosphorylation level in endometrial cancer.
    Zaczek A; Jóźwiak P; Ciesielski P; Forma E; Wójcik-Krowiranda K; Cwonda Ł; Bieńkiewicz A; Bryś M; Krześlak A
    J Cell Mol Med; 2020 Jan; 24(2):1300-1310. PubMed ID: 31863623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer.
    Couto SS; Cao M; Duarte PC; Banach-Petrosky W; Wang S; Romanienko P; Wu H; Cardiff RD; Abate-Shen C; Cunha GR
    Differentiation; 2009 Jan; 77(1):103-11. PubMed ID: 19281769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A balancing act: PHLPP2 fine tunes AKT activity and MYC stability in prostate cancer.
    Toivanen R; Furic L
    J Cell Biol; 2019 Jun; 218(6):1771-1772. PubMed ID: 31145683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN Protein Phosphatase Activity Is Not Required for Tumour Suppression in the Mouse Prostate.
    Wise HM; Harris A; Kriplani N; Schofield A; Caldwell H; Arends MJ; Overton IM; Leslie NR
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
    Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
    Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
    Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
    Luchman HA; Benediktsson H; Villemaire ML; Peterson AC; Jirik FR
    PLoS One; 2008; 3(12):e3940. PubMed ID: 19081794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irs2 inactivation suppresses tumor progression in Pten+/- mice.
    Szabolcs M; Keniry M; Simpson L; Reid LJ; Koujak S; Schiff SC; Davidian G; Licata S; Gruvberger-Saal S; Murty VV; Nandula S; Efstratiadis A; Kushner JA; White MF; Parsons R
    Am J Pathol; 2009 Jan; 174(1):276-86. PubMed ID: 19095950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
    González-Billalabeitia E; Seitzer N; Song SJ; Song MS; Patnaik A; Liu XS; Epping MT; Papa A; Hobbs RM; Chen M; Lunardi A; Ng C; Webster KA; Signoretti S; Loda M; Asara JM; Nardella C; Clohessy JG; Cantley LC; Pandolfi PP
    Cancer Discov; 2014 Aug; 4(8):896-904. PubMed ID: 24866151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer.
    Kim J; Eltoum IE; Roh M; Wang J; Abdulkadir SA
    PLoS Genet; 2009 Jul; 5(7):e1000542. PubMed ID: 19578399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protein kinase C super-family member PKN is regulated by mTOR and influences differentiation during prostate cancer progression.
    Yang CS; Melhuish TA; Spencer A; Ni L; Hao Y; Jividen K; Harris TE; Snow C; Frierson HF; Wotton D; Paschal BM
    Prostate; 2017 Nov; 77(15):1452-1467. PubMed ID: 28875501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.